Announcements Trials
Browse Landscape

Phase

Phase 3 25Phase 2 15Phase 4 3Phase 2/3 3Phase 1 3Phase EARLY_PHASE1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Flutamide × Genitourinary × Clear all
NCT00054106 2023-08-04

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Canadian Cancer Trials Group

Phase 1 Completed
25 enrolled
Genitourinary

Prostatic Neoplasms

NCT00026377 2013-09-05

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

University of Chicago

Phase 1 Completed
3 enrolled
Genitourinary

Prostatic Neoplasms

NCT00512668 2013-01-07

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
24 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡